STRIDES PHARMA SCIENCE Financial Statement Analysis
|
||
|
The Revenues of STRIDES PHARMA SCIENCE have decreased by -7.41% YoY .
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
STRIDES PHARMA SCIENCE Last 5 Annual Financial Results
[BOM: 532531|NSE : STAR]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹3,070 Cr | ₹3,316 Cr | ₹2,752 Cr | ₹2,178 Cr | ₹2,845 Cr |
| Expenses | ₹3,092 Cr | ₹2,689 Cr | ₹2,236 Cr | ₹1,936 Cr | ₹2,431 Cr |
| Operating Profit (Excl OI) | ₹-22 Cr | ₹627 Cr | ₹516 Cr | ₹242 Cr | ₹414 Cr |
| Other Income | ₹133 Cr | ₹59 Cr | ₹53 Cr | ₹41 Cr | ₹76 Cr |
| Interest | ₹177 Cr | ₹150 Cr | ₹156 Cr | ₹79 Cr | ₹196 Cr |
| Depreciation | ₹233 Cr | ₹206 Cr | ₹174 Cr | ₹117 Cr | ₹154 Cr |
| Profit Before Tax | ₹-653 Cr | ₹275 Cr | ₹55 Cr | ₹62 Cr | ₹80 Cr |
| Profit After Tax | ₹-474 Cr | ₹244 Cr | ₹43 Cr | ₹89 Cr | ₹74 Cr |
| Consolidated Net Profit | ₹-460 Cr | ₹268 Cr | ₹36 Cr | ₹325 Cr | ₹665 Cr |
| Earnings Per Share (Rs) | ₹-22.44 | ₹-51.25 | ₹29.93 | ₹4.06 | ₹36.25 |
| PAT Margin (%) | -3.70 | -8.90 | 4.45 | 0.92 | 2.67 |
| ROE(%) | -10.15 | -18.49 | 9.21 | 1.68 | 3.50 |
| ROCE(%) | -0.49 | -9.49 | 9.08 | 4.06 | 2.61 |
| Total Debt/Equity(x) | 1.27 | 1.18 | 0.76 | 0.78 | 1.22 |
Key Financials |
||
| Market Cap | : | ₹ 8,054.6 Cr |
| Revenue (TTM) | : | ₹ 3,953.5 Cr |
| Net Profit(TTM) | : | ₹ -4.9 Cr |
| EPS (TTM) | : | ₹ -0.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| STRIDES PHARMA SCIENCE | 3.6% | 13% | 161.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
STRIDES PHARMA SCIENCE Revenues
[BOM: 532531|NSE : STAR]
| Y-o-Y | -7.41 % |
| 5 Yr CAGR | 1.92 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹3,070 Cr | -7.41 | |
| Mar2022 | ₹3,316 Cr | 20.49 | |
| Mar2021 | ₹2,752 Cr | 26.33 | |
| Mar2020 | ₹2,178 Cr | -23.43 | |
| Mar2019 | ₹2,845 Cr | - | |
STRIDES PHARMA SCIENCE Operating Profit
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹-22 Cr | Negative | |
| Mar2022 | ₹627 Cr | 21.50 | |
| Mar2021 | ₹516 Cr | 112.91 | |
| Mar2020 | ₹242 Cr | -41.51 | |
| Mar2019 | ₹414 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | -0.7% | Negative | |
| Mar2022 | 18.9% | 0.80 | |
| Mar2021 | 18.75% | 68.62 | |
| Mar2020 | 11.12% | -23.63 | |
| Mar2019 | 14.56% | - | |
STRIDES PHARMA SCIENCE Profit After Tax
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹-460 Cr | Negative | |
| Mar2022 | ₹268 Cr | 637.66 | |
| Mar2021 | ₹36 Cr | -88.79 | |
| Mar2020 | ₹325 Cr | -51.15 | |
| Mar2019 | ₹665 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | -3.7 % | Negative | |
| Mar2022 | -8.9 % | Negative | |
| Mar2021 | 4.45 % | 383.70 | |
| Mar2020 | 0.92 % | -65.54 | |
| Mar2019 | 2.67 % | - | |
STRIDES PHARMA SCIENCE Earnings Per Share (EPS)
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹-22 | Negative | |
| Mar2022 | ₹-51 | Negative | |
| Mar2021 | ₹30 | 637.19 | |
| Mar2020 | ₹4.06 | -88.80 | |
| Mar2019 | ₹36 | - | |
STRIDES PHARMA SCIENCE Return on Capital Employed (ROCE)
[BOM: 532531|NSE : STAR]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | -0.49% | Negative | |
| Mar2022 | -9.49% | Negative | |
| Mar2021 | 9.08% | 123.65 | |
| Mar2020 | 4.06% | 55.56 | |
| Mar2019 | 2.61% | - | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Current Share Price | : | ₹876.5 |
| Current MarketCap | : | ₹ 8,054.6 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | 3.6% |
13% |
161.9% |
| SENSEX | 0.9% |
1.5% |
23.6% |
STRIDES PHARMA SCIENCE related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE SMALL CAP | 4% | 11.6% | 67.3% |
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
No NSE index found
You may also like the below Video Courses
FAQ about STRIDES PHARMA SCIENCE Financials
How the annual revenues of STRIDES PHARMA SCIENCE have changed ?
The Revenues of STRIDES PHARMA SCIENCE have decreased by -7.41% YoY .
How the Earnings per Share (EPS) of STRIDES PHARMA SCIENCE have changed?
The Earnings Per Share (EPS) of STRIDES PHARMA SCIENCE has decreased by Negative YoY .
Check out Intrinsic Value of Peers of STRIDES PHARMA SCIENCE
Compare Stock Analytics of Peers of STRIDES PHARMA SCIENCE
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
